ATAI adds MDMA biotech to growing list of psychedelic makers; Acadia adds $52.5M upfront pain buyout
For years, the biggest push in psychedelic drug development has been around MDMA, a party drug long thought to have potential benefits for patients with PTSD. Rick Doblin, for years psychedelic therapy’s most prominent advocate and fundraiser, and his non-profit, MAPS, have raised millions to advance clinical trials, most recently raising $30 million to complete a Phase III study in veterans.
But ATAI, the German-born biotech that has quickly become the most prominent private promoter and driver of psychedelic therapy, still thinks they have something to offer. Yesterday, the portfolio announced their latest subsidiary: EmpathBio.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.